Roche tries to pressure Illumina to start talking

Illumina ($ILMN) isn't the only game in town, and Roche could easily find other companies to acquire that are equally advanced in the gene-sequencing field, Roche ($RHHBY) Chairman Franz Humer told his company's shareholders Tuesday. As Reuters reports, Humer spoke during Roche's annual shareholders meeting in a not-so-subtle attempt to increase the pressure on gene-sequencing company Illumina to start talking with Roche about its $5.7 billion hostile bid. For now, Illumina is resisting the unsolicited bid with a "poison pill" strategy, Reuters notes. Meanwhile, some analysts pointed out to Reuters that while there are some alternatives, Illumina may be the best, most advanced acquisition target among them. Story

Suggested Articles

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.

The FDA has authorized its first COVID-19 antibody test for use in doctors' offices, urgent care centers and emergency rooms.

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.